Mhd Louai Manini, M.D.

Closed for Enrollment

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D) Rochester, Minn.

  The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating IBS-D in pediatric patients 12-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric patients with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric patients with IBS-D.

   

   

  

• The Role of Bile Acid Diarrhea in Adolescents with Irritable Bowel Syndrome Rochester, Minn.

  The purpose of this study is to measure 48 hour fecal bile acids in IBS-D adolescents and compare it to HC; measure serum C4 and FGF-19 in adolescents with IBS-D and HC and compare it to 48 hour fecal bile acid loss; measure primary bile acids concentration in 48 hour stool collection in adolescents with IBS-D and compare it to HC.